Home » Stocks » AKRO

Akero Therapeutics, Inc. (AKRO)

Stock Price: $27.21 USD -0.30 (-1.07%)
Updated May 13, 2021 3:24 PM EDT - Market open
Market Cap 967.31M
Revenue (ttm) n/a
Net Income (ttm) -79.21M
Shares Out 31.46M
EPS (ttm) -2.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $27.21
Previous Close $27.50
Change ($) -0.30
Change (%) -1.07%
Day's Open 27.51
Day's Range 26.83 - 28.15
Day's Volume 80,423
52-Week Range 20.45 - 41.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

-- 33% of patients treated with efruxifermin (EFX) (4 of 12) improved by one fibrosis stage without worsening of NASH -- -- 25% of EFX patients (3 of 12) showed NASH resolution --

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 22, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...

1 month ago - GlobeNewsWire

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic...

1 month ago - GlobeNewsWire

SAN FRANCISCO, Feb. 23, 2021 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic biotechnology company developing transformational treatments for non-alcoholic steatohepatitis (N...

2 months ago - PRNewsWire

SAN FRANCISCO--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steatohepatitis (NA...

4 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-alcoholic steat...

5 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced the presentation of additional data analysis from the Phase 2a BALANCED study at the Presidential Or...

6 months ago - Business Wire

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines design...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines design...

6 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Oct. 2, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designe...

7 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 28, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage biotechnology company developing transformational treatments for patients with non-a...

7 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines desig...

7 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2020 /PRNewswire/ -- Akero Therapeutics, Inc.

8 months ago - PRNewsWire

SAN FRANCISCO, Aug. 12, 2020 /PRNewswire/ -- Akero Therapeutics, Inc.

9 months ago - PRNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.

Other stocks mentioned: BBBY, PSTX, AZZ, GSK, NKTX, PRSP, TSE ...
9 months ago - Benzinga

SOUTH SAN FRANCISCO, Calif., July 10, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines design...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 7, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designe...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., July 6, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designe...

10 months ago - PRNewsWire

Akero Therapeutics Inc. (NASDAQ: AKRO) has only been public for about a year now, and despite shares surging over 30% to an all-time high in Wednesday’s session, analysts think this stock can go much hi...

10 months ago - 24/7 Wall Street

Akero Therapeutics charged up Wednesday after the biotech company unveiled promising results for a hepatitis treatment.

10 months ago - Investors Business Daily

Akero Therapeutics (AKRO) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

10 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 30, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced results of a 16-week analysis of secondary and exploratory endpoints in its Phase 2a BA...

10 months ago - PRNewsWire

SOUTH SAN FRANCISCO, Calif., June 29, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO) today announced that the company plans to discuss new efficacy and safety data, including biopsy result...

10 months ago - PRNewsWire

Akero Therapeutics, Inc. (AKRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

11 months ago - Zacks Investment Research

Is (AKRO) Outperforming Other Medical Stocks This Year?

11 months ago - Zacks Investment Research

Akero Therapeutics, Inc. (AKRO) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

11 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., June 10, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines design...

11 months ago - PRNewsWire

If you haven't heard of Akero Therapeutics before, take note. Its NASH drug candidate could be a game changer.

11 months ago - The Motley Fool

Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

11 months ago - Zacks Investment Research

SOUTH SAN FRANCISCO, Calif., May 26, 2020 /PRNewswire/ -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a cardio-metabolic non-alcoholic steatohepatitis (NASH) company developing pioneering medicines designe...

11 months ago - PRNewsWire

Akero Therapeutics Inc (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Akero Therapeutics: A Very Attractive Risk/Reward Opportunity

1 year ago - Seeking Alpha

Akero Therapeutics, Inc. (AKRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

1 year ago - Zacks Investment Research

Akero Therapeutics (AKRO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

A first-in-class new drug candidate for the treatment of non-alcoholic steatohepatitis produced some compelling clinical trial results.

1 year ago - The Motley Fool

Akero Therapeutics (AKRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 year ago - Zacks Investment Research

On Dec. 17, GuruFocus reported that in a July article, Kiplinger identified Morphic Holding Inc.

Other stocks mentioned: DERM, GBT, MRNA
1 year ago - GuruFocus

Akero Therapeutics shares opened at $16.16 Thursday morning after pricing of 5.75 million shares of common stock at $16.

1 year ago - Benzinga

About AKRO

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patient... [Read more...]

Industry
Biotechnology
IPO Date
Jun 20, 2019
Stock Exchange
NASDAQ
Ticker Symbol
AKRO
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for AKRO stock is "Strong Buy." The 12-month stock price forecast is 60.71, which is an increase of 123.16% from the latest price.

Price Target
$60.71
(123.16% upside)
Analyst Consensus: Strong Buy